COVID-19 vaccine effectiveness
(Randomized evidence)

Search studies

Search by Vaccine name Author Registration number
Trial Type Comparisons Design Participants Sample size Overall risk
of bias
Highest assessment
Full description
Intervention 1 Intervention 2
NCT04368728
Pfizer/BioNTech+Fosun Pharma
Frenck R, N Engl J Med, 2021 ()

Full text
Commentary
RNA based vaccine

BNT162b2 3mcg D0/21

Placebo D0/21

RCT
Phase 3
Adolescents aged 12 to 15 years with no previous Covid-19 diagnosis or SARS-CoV-2 infection in 29 centers in the USA N=2264
Some concerns
Details

Full description

NCT04588480
Pfizer/BioNTech+Fosun Pharma
Haranaka M, Nat. Commun., 2021 ()

Full text
Commentary
Commentary
RNA based vaccine

BNT162b2

Placebo

RCT
Phase 1-2
Adults including elderly and co-morbidities with no history of COVID-19 at 2 centres in Japan N=160
Low
Details

Full description

NCT04368728
Pfizer/BioNTech+Fosun Pharma
Polack F, N Engl J Med, 2020 ()

Full text
Commentary
; Commentary
; Commentary
; Commentary
; Commentary
RNA based vaccine

BNT162b2 10mcg D1/D21

Normal saline (0.9% sodium chloride) D1/D21

RCT
Phase 2/3
Healthy SARS-CoV-2 DNA negative adults in multiple centres in Argentina, Brazil, Germany, South Africa, Turkey, and the USA N=43448
Some concerns
Details

Full description

NCT04368728
Pfizer/BioNTech+Fosun Pharma
Thomas S, N Engl J Med, 2021 ()

Full text
Commentary
Commentary
RNA based vaccine

BNT162b2

Placebo

RCT
Phase 2-3
Children (>=12Y yo), adolescentes and adults, with no history or SARS-CoV 2 infection at 152 sites in Argentina, Brazil, Germany, South Africa, Turkey and USA N=44165
Some concerns
Details

Full description

NCT04523571 ; ChiCTR
Pfizer/BioNTech + Fosun Pharma
Zhu F, ResearchSquare, 2021 ()

Full text
Commentary
; Commentary
RNA based vaccine

BNT126b1 10 mcg/0.5 ml Days 0,21

Saline 0.5 m l Days 0,21

RCT
Phase 1
Healthy SARS-CoV-2 infection-free adults aged 18-55 and 65-85 at a single center in China N=144
Low
Details

Full description